The EIF2D Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the endogenous EIF2D (DENR) gene in the human renal cell carcinoma line 786-O. This polyclonal knockout model provides a heterogeneous pool of gene-edited cells, enabling the study of EIF2D loss-of-function without the selection biases of monoclonal lines. The CRISPR/Cas9 system introduces targeted gene disruption, resulting in a versatile tool for investigating EIF2D-dependent translational control mechanisms and oncogenic adaptations.
The 786-O host cell line is derived from a primary clear cell renal cell carcinoma (ccRCC) and is characterized by a homozygous VHL mutation, leading to stabilization of hypoxia-inducible factors (HIFs) under normoxic conditions. These adherent epithelial cells exhibit hallmark features of ccRCC, including constitutive activation of hypoxia-responsive pathways and mTORC1 signaling. The VHL deficiency renders 786-O cells particularly dependent on cap-independent translation mechanisms for the expression of pro-survival and angiogenic factors, making them an ideal background for dissecting EIF2D function.
EIF2D functions as a translation initiation factor that specifically mediates cap-independent translation through internal ribosome entry sites (IRES) and participates in ribosome recycling by facilitating subunit dissociation. EIF2D interacts with MCTS1, eIF2, eIF3, eIF5B, and the 40S ribosomal subunit, forming complexes that are regulated by nutrient deprivation and hypoxia via upstream sensors mTORC1, PERK, and GCN2. Under stress conditions, EIF2D promotes the translation of IRES-containing mRNAs encoding HIF1A, VEGFA, MYC, and other stress-response transcripts, thereby linking translational control to oncogenic signaling and the unfolded protein response.
In the VHL-deficient 786-O ccRCC model, EIF2D knockout is expected to disrupt the cap-independent translation of key oncogenic drivers that are typically upregulated under pseudo-hypoxic conditions. By eliminating EIF2D, the polyclonal knockout cells may exhibit reduced expression of HIF1A and VEGFA, impairing angiogenic potential and altering stress adaptation. This model provides a unique platform to dissect the reliance of renal carcinoma cells on IRES-mediated translation and to evaluate EIF2D as a potential therapeutic target within the mTOR-eIF2?? signaling axis.
Researchers can employ this knockout model for polysome profiling to assess global translation changes, luciferase-based IRES reporter assays to directly measure cap-independent translation activity, and ribosome footprinting to map ribosome occupancy on specific transcripts. Complementary assays such as western blotting for downstream targets (e.g., HIF1A, MYC, VEGFA) and functional studies including cell proliferation, migration, and invasion assays allow comprehensive phenotypic characterization. This product is suitable for investigating stress-induced translational reprogramming, identifying IRES-dependent oncogenic mRNAs, and screening for compounds targeting the translational machinery in renal cell carcinoma. For further details or technical inquiries, please contact Ascent Research.
